CCL4 and B-cell chronic lymphocytic leukemia: In addition, ibrutinib not only inhibits the secretion of chemokines, such as CCL3, CCL4, CXCL12 and CXCL13, from CLL cells and their supporting cells but also inhibits the TLR signaling pathway.